Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1983 Oct;46(10):905–910. doi: 10.1136/jnnp.46.10.905

Central catecholamine metabolism in vivo and the cognitive and motor deficits in Parkinson's disease.

J J Mann, M Stanley, R D Kaplan, J Sweeney, A Neophytides
PMCID: PMC1027603  PMID: 6644314

Abstract

Cerebrospinal fluid levels of homovanillic acid (HVA) in unmedicated patients with Parkinson's disease were 45% of levels in control subjects. Levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and platelet monoamine oxidase activity (MAO) did not differ. Within the Parkinson's disease group platelet MAO B activity correlated with HVA (an MAO B substrate) but not MHPG (an MAO A substrate). A mild global dementia was found that did not correlate with the more severe motor deficit. There was a negative correlation between the motor deficit and HVA levels but not with MHPG. Cognitive functioning correlated positively with platelet MAO, and the ratio of HVA to MHPG levels and negatively with MHPG alone. It is postulated that dopaminergic and noradrenergic activity or the functional balance between these systems may contribute to the observed cognitive dysfunction.

Full text

PDF
910

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antelman S. M., Caggiula A. R. Norepinephrine-dopamine interactions and behavior. Science. 1977 Feb 18;195(4279):646–653. doi: 10.1126/science.841304. [DOI] [PubMed] [Google Scholar]
  2. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 1973 Dec;20(4):415–455. doi: 10.1016/0022-510x(73)90175-5. [DOI] [PubMed] [Google Scholar]
  3. Bowers M. B., Jr, Gerbode F. A. Relationship of monoamine metabolites in human cerebrospinal fluid to age. Nature. 1968 Sep 21;219(5160):1256–1257. doi: 10.1038/2191256a0. [DOI] [PubMed] [Google Scholar]
  4. Davidson D. L., Yates C. M., Mawdsley C., Pullar I. A., Wilson H. CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders. J Neurol Neurosurg Psychiatry. 1977 Dec;40(12):1136–1141. doi: 10.1136/jnnp.40.12.1136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Donnelly E. F., Chase T. N. Intellectual and memory function in parkinsonian and non-parkinsonian patients treated with L-dopa. Dis Nerv Syst. 1973 Feb;34(2):119–123. [PubMed] [Google Scholar]
  6. Gilbert J. G., Levee R. F. Patterns of declining memory. J Gerontol. 1971 Jan;26(1):70–75. doi: 10.1093/geronj/26.1.70. [DOI] [PubMed] [Google Scholar]
  7. Guldberg H. C., Turner J. W., Hanieh A., Ashcroft G. W., Crawford T. B., Perry W. L., Gillingham F. J. On the occurrence of homovanillic acid and 5-hydroxyindol-3-ylacetic acid in the ventricular C.S.F. of patients suffering from parkinsonism. Confin Neurol. 1967;29(2):73–77. doi: 10.1159/000103680. [DOI] [PubMed] [Google Scholar]
  8. Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427–442. doi: 10.1212/wnl.17.5.427. [DOI] [PubMed] [Google Scholar]
  9. Johansson B., Roos B. E. 5-hydroxyindoleacetic and homovanillic acid levels in the cerebrospinal fluid of healthy volunteers and patients with Parkinson's syndrome. Life Sci. 1967 Jul 1;6(13):1449–1454. doi: 10.1016/0024-3205(67)90193-2. [DOI] [PubMed] [Google Scholar]
  10. KAHN R. L., GOLDFARB A. I., POLLACK M., PECK A. Brief objective measures for the determination of mental status in the aged. Am J Psychiatry. 1960 Oct;117:326–328. doi: 10.1176/ajp.117.4.326. [DOI] [PubMed] [Google Scholar]
  11. Kienzl E., Riederer P., Jellinger K., Wesemann W. Transitional states of central serotonin receptors in Parkinson's disease. J Neural Transm. 1981;51(1-2):113–122. doi: 10.1007/BF01664009. [DOI] [PubMed] [Google Scholar]
  12. Lloyd K., Hornykiewicz O. Parkinson's disease: activity of L-dopa decarboxylase in discrete brain regions. Science. 1970 Dec 11;170(3963):1212–1213. doi: 10.1126/science.170.3963.1212. [DOI] [PubMed] [Google Scholar]
  13. Loranger A. W., Goodell H., Lee J. E., McDowell F. Levodopa treatment of Parkinson's syndrome. Improved intellectual functioning. Arch Gen Psychiatry. 1972 Feb;26(2):163–168. doi: 10.1001/archpsyc.1972.01750200067014. [DOI] [PubMed] [Google Scholar]
  14. Mann J. J., Kaplan R. D., Georgotas A., Friedman E., Branchey M., Gershon S. Monoamine oxidase activity and enzyme kinetics in three subpopulations of density-fractionated platelets in chronic paranoid schizophrenics. Psychopharmacology (Berl) 1981;74(4):344–348. doi: 10.1007/BF00432744. [DOI] [PubMed] [Google Scholar]
  15. Mann J. J., Stanley M., Neophytides A., de Leon M. J., Ferris S. H., Gershon S. Central amine metabolism in Alzheimer's disease: in vivo relationship to cognitive deficit. Neurobiol Aging. 1981 Spring;2(1):57–60. doi: 10.1016/0197-4580(81)90060-9. [DOI] [PubMed] [Google Scholar]
  16. Marttila R. J., Rinne U. K. Dementia in Parkinson's disease. Acta Neurol Scand. 1976 Nov;54(5):431–441. doi: 10.1111/j.1600-0404.1976.tb04375.x. [DOI] [PubMed] [Google Scholar]
  17. Meier M. J., Martin W. E. Intellectual changes associated with levodopa therapy. JAMA. 1970 Jul 20;213(3):465–466. [PubMed] [Google Scholar]
  18. Oreland L., Wiberg A., Asberg M., Träskman L., Sjöstrand L., Thorén P., Bertilsson L., Tybring G. Platelet MAO activity and monoamine metabolites in cerebrospinal fluid in depressed and suicidal patients and in healthy controls. Psychiatry Res. 1981 Feb;4(1):21–29. doi: 10.1016/0165-1781(81)90004-4. [DOI] [PubMed] [Google Scholar]
  19. Papeschi R., Molina-Negro P., Sourkes T. L., Hardy J., Bertrand C. Concentration of homovanillic acid in the ventricular fluid of patients with Parkinson's disease and other dyskinesias. Neurology. 1970 Oct;20(10):991–995. doi: 10.1212/wnl.20.10.991. [DOI] [PubMed] [Google Scholar]
  20. Parkes J. D., Marsden C. D., Rees J. E., Curzon G., Kantamaneni B. D., Knill-Jones R., Akbar A., Das S., Kataria M. Parkinson's disease, cerebral arteriosclerosis, and senile dementia. Clinical features and response to levodopa. Q J Med. 1974 Jan;43(169):49–61. [PubMed] [Google Scholar]
  21. Riederer P., Birkmayer W., Seemann D., Wuketich S. Brain-noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's syndrome. J Neural Transm. 1977;41(4):241–251. doi: 10.1007/BF01252019. [DOI] [PubMed] [Google Scholar]
  22. Rinne U. K., Lönnberg P., Koskinen V. Dopamine receptors in the Parkinsonian brain. J Neural Transm. 1981;51(1-2):97–106. doi: 10.1007/BF01664007. [DOI] [PubMed] [Google Scholar]
  23. Robinson D. S., Sourkes T. L., Nies A., Harris L. S., Spector S., Bartlett D. L., Kaye I. S. Monoamine metabolism in human brain. Arch Gen Psychiatry. 1977 Jan;34(1):89–92. doi: 10.1001/archpsyc.1977.01770130091009. [DOI] [PubMed] [Google Scholar]
  24. Shoulson I., Chase T. N. Clonidine and the anti-parkinsonian response to L-DOPA or piribedil. Neuropharmacology. 1976 Jan;15(1):25–27. doi: 10.1016/0028-3908(76)90093-9. [DOI] [PubMed] [Google Scholar]
  25. Stein L., Belluzzi J. D., Wise C. D. Memory enhancement by central administration of norepinephrine. Brain Res. 1975 Feb 7;84(2):329–335. doi: 10.1016/0006-8993(75)90989-0. [DOI] [PubMed] [Google Scholar]
  26. Tabaddor K., Wolfson L. I., Sharpless N. S. Ventricular fluid homovanillic acid and 5-hydroxyindoleacetic acid concentrations in patients with movement disorders. Neurology. 1978 Dec;28(12):1249–1253. doi: 10.1212/wnl.28.12.1249. [DOI] [PubMed] [Google Scholar]
  27. Taquet H., Javoy-Agid F., Cesselin F., Agid Y. Methionine-enkephalin deficiency in brains of patients with Parkinson's disease. Lancet. 1981 Jun 20;1(8234):1367–1368. doi: 10.1016/s0140-6736(81)92543-5. [DOI] [PubMed] [Google Scholar]
  28. Watson E., Wilk S. Assessment of cerebrospinal fluid levels of dopamine metabolites by gas chromatography. Psychopharmacologia. 1975 Apr 30;42(1):57–56. doi: 10.1007/BF00428826. [DOI] [PubMed] [Google Scholar]
  29. Zeller E. A., Boshes B., Arbit J., Bieber M., Blonsky E. R., Dolkart M., Huprikar S. V. Molecular biology of neurological and psychiatric disorders. I. Effect of parkinsonism, age, sex and L-dopa on platelet monoamine oxidase. J Neural Transm. 1976;39(1-2):63–77. doi: 10.1007/BF01248766. [DOI] [PubMed] [Google Scholar]
  30. van Woert M. H., Bowers M. B., Jr The effect of L-dopa on monoamine metabolites in Parkinson's disease. Experientia. 1970;26(2):161–163. doi: 10.1007/BF01895555. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES